Biohaven’s Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
- Monday, February 10, 2020, 7:29
- Finance
- Add a comment
NEW HAVEN, Conn., Feb. 10, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today reported negative topline results from its Phase 3 clinical trial evaluating troriluzole compared to placebo for the treatment of patients with Generalized Anxiety Disorder…
About the Author
adminasapcorp has written 41755 stories on this site.